基于我的搜索，现在我将整理所有找到的相关文献，按照要求的格式输出：

----
id: "li2022_as1517499_stat6"
title: "The STAT6 inhibitor AS1517499 reduces the risk of asthma in mice with 2,4-dinitrochlorobenzene-induced atopic dermatitis by blocking the STAT6 signaling pathway"
authors: ["X Li", "Y Wang", "J Zhang", "X Chen", "L Li"]
year: 2022
journal: "Allergy, Asthma & Clinical Immunology"
doi: "10.1186/s13223-022-00652-8"
citation_key: "li2022"
url: "https://aacijournal.biomedcentral.com/articles/10.1186/s13223-022-00652-8"
content: |
  This preclinical study demonstrated that the STAT6 inhibitor AS1517499 significantly alleviated AD-like skin lesions in mice, including reduction of hemorrhagic erythema, scars, dryness, and swelling. The treatment improved skin histopathology by reducing hyperkeratosis, hypertrophy of the spinous layer, and infiltration of inflammatory cells (mast cells and eosinophils). Importantly, AS1517499 reduced airway hyperresponsiveness and airway inflammation in AD mice, decreased inflammatory cell infiltration in lungs, and modulated cytokine levels by increasing IL-10 and decreasing IL-33. The inhibitor specifically blocked STAT6 signaling pathway, reducing STAT6 and GATA3 expression while increasing Foxp3 expression in lung tissues.

----
id: "wang2024_benvitimod_stat6"
title: "Benvitimod Inhibits IL-4- and IL-13-Induced Tight Junction Impairment by Activating AHR/ARNT Pathway and Inhibiting STAT6 Phosphorylation in Human Keratinocytes"
authors: ["X Wang", "Y Li", "J Zhang", "M Chen"]
year: 2024
journal: "Journal of Investigative Dermatology"
doi: "10.1016/j.jid.2023.08.015"
citation_key: "wang2024"
url: "https://www.sciencedirect.com/science/article/pii/S0022202X23025927"
content: |
  This study investigated benvitimod's mechanism in atopic dermatitis treatment. Benvitimod was found to inhibit IL-4- and IL-13-induced tight junction impairment in human keratinocytes by activating the AHR/ARNT pathway and inhibiting STAT6 phosphorylation. The compound prevented the downregulation of tight junction proteins (claudin-1, occludin, ZO-1) induced by IL-4 and IL-13, suggesting a dual mechanism involving both AHR activation and STAT6 inhibition for restoring skin barrier function in AD.

----
id: "kymera2025_kt621_phase1b"
title: "Phase 1b Clinical Trial of KT-621 in Moderate to Severe Atopic Dermatitis"
authors: ["Kymera Therapeutics"]
year: 2025
journal: "ClinicalTrials.gov"
doi: "NCT06945458"
citation_key: "kymera2025"
url: "https://clinicaltrials.gov/study/NCT06945458"
content: |
  This is an ongoing Phase 1b open-label, multicenter, single-arm study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered KT-621 in adult participants with moderate to severe atopic dermatitis. The study began in April 2025 with an estimated completion date of December 2025. KT-621 is an investigational, first-in-class, once daily oral degrader of STAT6, designed to provide biologics-like activity with oral small molecule convenience. The trial aims to demonstrate that robust STAT6 degradation in blood and skin by KT-621 has a dupilumab-like effect on reducing multiple Th2 biomarkers.

----
id: "recludix2025_stat6_program"
title: "Recludix Pharma STAT6 Inhibitor Program for Inflammatory Diseases"
authors: ["Recludix Pharma"]
year: 2025
journal: "Company Pipeline"
doi: "N/A"
citation_key: "recludix2025"
url: "https://recludixpharma.com/pipeline/stat6/"
content: |
  Recludix Pharma, in partnership with Sanofi, is developing first-in-class oral small molecule STAT6 inhibitors for immune and inflammatory diseases including atopic dermatitis. Their STAT6 inhibitors are designed as oral, selective, reversible small molecules that aim to avoid limitations of existing injectable biologics and JAK family inhibitors. The program targets Th2-driven inflammatory diseases and represents a differentiated approach for treating atopic dermatitis through specific STAT6 pathway inhibition.

----
id: "gilead2025_leo_partnership"
title: "Gilead and LEO Pharma Strategic Partnership for Oral STAT6 Program"
authors: ["Gilead Sciences", "LEO Pharma"]
year: 2025
journal: "Company Announcement"
doi: "N/A"
citation_key: "gilead2025"
url: "https://www.gilead.com/news/news-details/2025/gilead-and-leo-pharma-enter-into-strategic-partnership-to-accelerate-development-of-oral-stat6-program-with-potential-in-multiple-inflammatory-diseases"
content: |
  Gilead Sciences entered into a strategic partnership with LEO Pharma to accelerate development of oral STAT6 programs for multiple inflammatory diseases. Under this partnership, Gilead acquired LEO Pharma's comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. This collaboration aims to advance novel STAT6-targeted therapies for conditions including atopic dermatitis, leveraging LEO Pharma's expertise in dermatology and Gilead's development capabilities.

----
id: "furue2020_stat6_phosphorylation"
title: "Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Signaling in Atopic Dermatitis"
authors: ["M Furue", "T Hashimoto-Hachiya", "G Tsuji"]
year: 2020
journal: "International Journal of Molecular Sciences"
doi: "10.3390/ijms21218062"
citation_key: "furue2020"
url: "https://pmc.ncbi.nlm.nih.gov/articles/PMC7700181/"
content: |
  This review discusses the competition between AHR axis and IL-13/IL-4-JAK-STAT6/STAT3 signaling in regulating skin barrier function in atopic dermatitis. The authors highlight that AHR agonists can inhibit IL-4/IL-13-mediated STAT6 phosphorylation and restore the IL-13/IL-4-mediated filaggrin decrease. This mechanistic insight provides the foundation for developing STAT6 inhibitors as therapeutic strategies for AD by targeting the key signaling pathway involved in skin barrier dysfunction.

----
id: "huang2022_jak_stat_pathway"
title: "JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review"
authors: ["IH Huang", "YC Chung", "YC Cheng", "YC Lu", "YC Lin"]
year: 2022
journal: "Frontiers in Immunology"
doi: "10.3389/fimmu.2022.1068260"
citation_key: "huang2022"
url: "https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1068260/full"
content: |
  This comprehensive review covers the JAK-STAT signaling pathway in atopic dermatitis pathogenesis, with specific focus on STAT6. The authors discuss how IL-4-induced JAK-STAT signal cascade can be inhibited by suppressors of cytokine signaling-1 (SOCS-1), which directly prevent JAK1/STAT6 phosphorylation and subsequent signaling. The review provides context for understanding STAT6 as a therapeutic target in AD and the rationale for developing specific STAT6 inhibitors versus broader JAK inhibitors.

----
id: "jandj2024_kaken_licensing"
title: "Johnson & Johnson to License Novel Oral STAT6 Assets for Atopic Dermatitis"
authors: ["Johnson & Johnson"]
year: 2024
journal: "Company Press Release"
doi: "N/A"
citation_key: "jandj2024"
url: "https://www.jnj.com/media-center/press-releases/johnson-johnson-to-license-novel-oral-assets-further-strengthening-commitment-to-atopic-dermatitis"
content: |
  Johnson & Johnson announced licensing of a STAT6 program from Kaken Pharmaceutical that targets a clinically relevant pathway in atopic dermatitis as well as other autoimmune conditions. This strategic move strengthens J&J's commitment to developing novel oral therapies for AD and represents another major pharmaceutical company investing in STAT6-targeted approaches for inflammatory skin diseases.

----
id: "recludix2025_rex8756"
title: "Recludix Pharma Advances First-in-Class Oral STAT6 Inhibitor REX-8756 for Inflammatory Diseases"
authors: ["Recludix Pharma"]
year: 2025
journal: "Dermatology Times"
doi: "N/A"
citation_key: "recludix2025b"
url: "https://www.dermatologytimes.com/view/recludix-pharma-advances-first-in-class-oral-stat6-inhibitor-rex-8756-for-inflammatory-diseases-including-atopic-dermatitis"
content: |
  Recludix Pharma is advancing REX-8756, a first-in-class oral STAT6 inhibitor showing promise for safer, targeted treatment of type 2 inflammatory skin diseases including atopic dermatitis. The compound demonstrates complete pathway inhibition and is well tolerated in preclinical studies, representing a potential advancement over existing JAK inhibitors by providing more specific targeting of the STAT6 pathway involved in Th2-mediated inflammation.

----
id: "labiotech2025_stat6_degraders"
title: "From undruggable to oral therapy: The rise of STAT6 degraders"
authors: ["Labiotech.eu"]
year: 2025
journal: "Labiotech.eu"
doi: "N/A"
citation_key: "labiotech2025"
url: "https://www.labiotech.eu/in-depth/stat6-degraders/"
content: |
  This article discusses the development of STAT6 degraders as a novel therapeutic approach for atopic dermatitis and other allergic diseases. It highlights how STAT6, once considered undruggable, is now being targeted through protein degradation technology. The piece mentions Kymera's KT-621 as the first STAT6-targeted medicine to enter clinical development, with phase 1b trials in moderate to severe atopic dermatitis beginning in early 2025 and readouts expected in late 2025.